Insmed reported $-314.19M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -314.19M 31.48M Dec/2025
Novartis USD 5.84B 235M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025